Cipla Harvard Case Solution & Analysis

The head of Cipla, $ 325-million Indian pharmaceutical company and seller of cheap AIDS drugs in South Africa, have to decide what to do with the future of Cipla's. With India ready to comply with international patents in two years, much of the product line Cipla could become unsaleable (given that it is based on the product is protected by patents in developed countries). Describes the role of a global pharmaceutical Cipla forcing companies to reduce the price of AIDS drugs. "Hide
by Rohit Deshpande, Laura Winig Source: Harvard Business School 21 pages. Publication Date: June 23, 2003. Prod. #: 503085-PDF-ENG

Cipla Case Solution Other Similar Case Solutions like


Share This